GlassScriptPhysician profile
Frank Taliercio
NPI 1417949504
$5,368.96
in general payments reported to CMS, 2019-2025
17 companies · $865 in 2025
The $865 reported for 2025 was more than what 86% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $129 · 2021: $323 · 2022: $1,527 · 2023: $776 · 2024: $720 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $2,116.98 | 2019-2025 | Aklief, Twyneo, Epsolay |
| Incyte Corporation | $1,388.29 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $456.41 | 2023-2024 | Vtama |
| Abbvie INC. | $285.72 | 2022 | |
| Journey Medical Corporation | $250.00 | 2022 | |
| Pfizer INC. | $205.97 | 2022-2025 | |
| Botanix Sb INC | $125.00 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2025 | |
| Almirall LLC | $124.96 | 2019 | |
| Janssen Biotech, INC. | $118.57 | 2024 | Tremfya |
| Biofrontera INC. | $34.51 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $30.00 | 2019 | |
| Dusa Pharmaceuticals, INC. | $24.05 | 2019 | |
| Genentech USA, INC. | $23.03 | 2019 | |
| Amgen INC. | $22.94 | 2024 | Otezla |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.36 | 2023 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $16.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Taliercio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.